GeoVax Labs, Inc. (Nasdaq: GOVX) reported financial results for the second quarter ended June 30, 2026, and provided a business update emphasizing continued execution toward the planned initiation of a pivotal immunobridging study for its lead vaccine candidate, GEO-MVA, under an expedited regulatory pathway established through formal Scientific Advice discussions with the European Medicines Agency (EMA). The company also highlighted advancements in its Gedeptin immuno-oncology program.
During the quarter, GeoVax advanced operational initiatives supporting the expected fourth-quarter 2026 start of the GEO-MVA pivotal study. These included clinical study readiness activities, manufacturing preparedness, and utilization of previously manufactured and released cGMP clinical trial material. The company also progressed its AGE1 continuous cell-line manufacturing platform for future commercial-scale MVA vaccine production and engaged with government, public health, and biodefense stakeholders regarding long-term orthopoxvirus preparedness and vaccine supply requirements.
“During the second quarter, we continued executing against what we believe is one of our most important value-creating milestones, as we prepare to initiate the pivotal GEO-MVA immunobridging study,” said David A. Dodd, Chairman and CEO of GeoVax. “Our priorities remain clear: completing the activities necessary to initiate the study, maintaining disciplined capital allocation, and positioning GEO-MVA to address the growing global need for diversified MVA vaccine supply supporting public health preparedness and biodefense.”
In the immuno-oncology space, GeoVax continued advancing Gedeptin, its investigational gene-directed enzyme prodrug therapy (GDEPT), toward combination immunotherapy strategies designed to enhance immune checkpoint inhibitor activity in solid tumors. The company believes Gedeptin’s localized tumor-targeting mechanism and immune activation profile may complement PD-1-based therapies, such as Merck’s Keytruda, by improving responsiveness in immunologically resistant tumors. GeoVax holds an exclusive intellectual property license from Emory University covering Gedeptin in combination with immune checkpoint inhibitors.
GeoVax reported a net loss of $4.4 million for the second quarter of 2026, or $0.97 per share, compared to a net loss of $5.4 million, or $8.74 per share, for the same period in 2025. The company reported no revenue from government contracts in the 2026 quarter, compared to $0.9 million in the prior-year period, following the termination of its BARDA contract for the GEO-CM04S1 COVID-19 vaccine program in April 2025. Research and development expenses decreased to $3.1 million from $4.7 million, primarily due to lower costs associated with discontinued BARDA activities and reduced GEO-CM04S1 clinical spending. General and administrative expenses decreased to $1.3 million from $1.5 million, driven by lower investor relations consulting costs and stock-based compensation. As of June 30, 2026, cash and cash equivalents stood at $3.1 million, unchanged from December 31, 2025.
In May 2026, GeoVax announced a strategic reprioritization to concentrate resources on its lead programs, GEO-MVA and Gedeptin, and discontinued active development of its GEO-CM04S1 COVID-19 vaccine candidate due to the evolving global COVID-19 vaccine market. The company stated that the decision was not related to any safety or efficacy concerns.
Additional information is included in the company’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission. For more information, visit www.geovax.com.
